BriaCell Therapeutics director buys
CANADIAN DAILY STOCK REPORT
Corporate Wire Date: 02 March 2017 04:32 EST
BriaCell Therapeutics (TSXV:BCT) director Williams, William bought 50,000 shares worth CAD7,000 on February 23.
SECTION 1 BRIACELL THERAPEUTICS ACTIVITIES
BriaCell Therapeutics Corp is a immuno oncology biotechnologu company with a focus on cancer immunotherapy. It has developed a patented whole-cell cancer vaccine,called the 'BriaVax' vaccine.
SECTION 2 BRIACELL THERAPEUTICS RECENT PRESS RELE...